EFFICACY AND TOLERANCE OF LONG-TERM, HIGH-DOSE GABAPENTIN - ADDITIONAL OBSERVATIONS

被引:50
作者
HANDFORTH, A
TREIMAN, DM
机构
[1] W LOS ANGELES VET AFFAIRS MED CTR,RES SERV,LOS ANGELES,CA 90073
[2] UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90024
关键词
EPILEPSY; PARTIAL-ONSET SEIZURES; GABAPENTIN; ANTIEPILEPTIC DRUGS; PSYCHOSTIMULATION; ADVERSE EVENTS; TOLERANCE;
D O I
10.1111/j.1528-1157.1994.tb02551.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Gabapentin (GBP) has shown antiepileptic efficacy and good tolerance in clinical trials. Much remains to be learned about its clinical use. As a participating center in the US Gabapentin Study Group, we report observations that have practical implications for patient management. Twenty-three patients with intractable partial-onset seizures initiated open-label treatment after a blinded placebo-controlled add-on dose efficacy study. In the titration phase, GBP and concurrent antiepileptic drugs (AEDs) were adjusted to achieve optimal efficacy on maximally tolerated GBP doses. Nine patients had no significant improvement in seizure control and discontinued GBP. The remaining 14 patients were observed while treated long-term with stable-dose GBP and concurrent AEDs. Improvement was maintained as long as patients were followed: less than or equal to 4 years. The protocol-allowed upper dose limit, 2,400 mg/day, was well tolerated by 16 of 23 patients, indicating that higher doses may be tolerated. GBP discontinuation did net cause rebound increases in seizure frequency. The most common adverse events (AEs) (in 14 of 23) were similar to those induced by concurrent AEDs and responded to reduction of concurrent AEDs. Many patients reported positive psychostimulatory effects. These observations extend previous findings indicating that GBP is an effective and well-tolerated drug for treatment of partial-onset seizures.
引用
收藏
页码:1032 / 1037
页数:6
相关论文
共 13 条
[1]  
[Anonymous], 1994, EPILEPSY RES, V18, P67
[2]   GABAPENTIN AS AN ANTIEPILEPTIC DRUG IN MAN [J].
CRAWFORD, P ;
GHADIALI, E ;
LANE, R ;
BLUMHARDT, L ;
CHADWICK, D .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1987, 50 (06) :682-686
[3]  
HANDFORTH A, 1989, Neurology, V39, P114
[4]   LACK OF A PHARMACOKINETIC INTERACTION BETWEEN PHENOBARBITONE AND GABAPENTIN [J].
HOOPER, WD ;
KAVANAGH, MC ;
HERKES, GK ;
EADIE, MJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (02) :171-174
[5]   LONG-TERM TREATMENT WITH GABAPENTIN FOR PARTIAL EPILEPSY [J].
OJEMANN, LM ;
WILENSKY, AJ ;
TEMKIN, NR ;
CHMELIR, T ;
RICKER, BA ;
WALLACE, J .
EPILEPSY RESEARCH, 1992, 13 (02) :159-165
[6]   PSYCHOLOGICAL STATUS RELATED TO SURGICAL CONTROL OF TEMPORAL-LOBE SEIZURES [J].
RAUSCH, R ;
CRANDALL, PH .
EPILEPSIA, 1982, 23 (02) :191-202
[7]  
SALETU B, 1986, INT J CLIN PHARM TH, V24, P362
[8]  
SCHMIDT B, 1989, ANTIEPILEPTIC DRUGS, P925
[9]   DOUBLE-BLIND-STUDY OF GABAPENTIN IN THE TREATMENT OF PARTIAL SEIZURES [J].
SIVENIUS, J ;
KALVIAINEN, R ;
YLINEN, A ;
RIEKKINEN, P .
EPILEPSIA, 1991, 32 (04) :539-542
[10]  
VOLLMER KO, 1986, ARZNEIMITTEL-FORSCH, V36-1, P830